In first-line therapy, our data showed higher ORR with MET inhibitors (40%) than non-MET inhibitor regimens (23.1%) in patients with METex14 skipping NSCLC, with the opposite trend in second-line (25% and 33.3%, respectively). The gene discussed is MET; the disease is non-small cell lung carcinoma.